Investigating how specific mutations affect heart function in hypertrophic cardiomyopathy.
Official title: Mutation-Specific Calmodulin Kinase II Activation in Hypertrophic Cardiomyopathy
Funded at University of Arizona · NIH-11064966 · Data updated 2026-11-12
This study is looking at how certain genetic changes in heart proteins affect a key enzyme that helps your heart work properly, with the goal of finding better treatments for people with hypertrophic cardiomyopathy (HCM).
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project start | June 1, 2025 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $41,607 |
| NIH project number | 1F31HL178018-01 |
| Project ID | NIH-11064966 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with hypertrophic cardiomyopathy, particularly those with known genetic mutations.
✕Less likely to help
Patients without hypertrophic cardiomyopathy or those whose condition is not linked to specific genetic mutations may not benefit from this research.
What this research studies
This research focuses on hypertrophic cardiomyopathy (HCM), a genetic heart condition that affects many individuals worldwide. It aims to understand how specific mutations in heart proteins influence the activation of a key enzyme, CaMKIIδ, which plays a role in heart muscle contraction and overall heart function. By studying these mutations, the research seeks to uncover mechanisms that could lead to targeted therapies for patients with HCM. Patients may benefit from insights into their specific genetic mutations and how these affect their condition.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment options for patients with hypertrophic cardiomyopathy based on their specific genetic mutations.
How similar studies have gone: Previous research has shown promising results in understanding the role of specific mutations in cardiac diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Arizona
Tucson, United States Active
Researchers
- Principal investigator: Hauck, Garrett Turner — University of Arizona
- Study coordinator: Hauck, Garrett Turner
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.